Cureus
2026
Mohsin Raza, Jasleen Kaur
Psychedelic-assisted therapies have re-emerged as a subject of increasing scientific and clinical interest in psychiatry, particularly in the context of persistent treatment gaps for conditions such as treatment-resistant depression, post-traumatic stress disorder, and substance use disorders. Compounds, including psilocybin and 3,4-methylenedioxymethamphetamine, are being evaluated in...
Annals of Medicine and Surgery
2026
Sana Rasheed, Rida Arif, Ahmed Asad Raza et al.
1 citation
Psilocybin, a naturally occurring psychedelic compound, has received attention as a novel therapeutic option for major depressive disorder (MDD), particularly in cases where traditional treatments prove ineffective. The study aims to evaluate psilocybin's therapeutic potential by examining its efficacy, safety, and mechanisms of action as well as addressing the societal and regulatory...
Harm Reduction Journal
December 9, 2025
Eirini K. Argyri, Joy Krecké, Oliver Robinson et al.
4 citations
Background: As the use of psychedelics increases in both therapeutic and non-clinical settings, reports of extended post-experience difficulties have also emerged. While many individuals integrate their experiences effectively, others face persistent challenges. Despite growing recognition of these issues, there is limited research on best practices for mitigating and addressing prolonged...
Iranian Journal of Chemistry & Chemical Engineering
December 7, 2025
Sajedeh Rabipour, Evan Abdolkareem Mahmood, Abdol Ghaffar Ebadi et al.
To aid the therapeutic process, illicit chemical substances and drugs are used in drug therapy. Various cultures have used illegal substances for thousands of years in medicine and various practices. The present study is a general approach to pharmaceutical science and attempts to contextualize drug-assisted therapy through an integrative literature review. All related articles were found...
EClinicalMedicine
December 1, 2025
Nadav Liam Modlin, Victoria Williamson, Guy M. Goodwin et al.
2 citations
Post-traumatic stress disorder (PTSD) is a debilitating condition leading to significant personal and societal burden. Standard treatments frequently demonstrate limited efficacy, leading to persistent symptoms and high dropout rates. Psilocybin has shown promise in treating depression, a condition that is often comorbid with PTSD. We aimed to explore participant experiences of psilocybin...
Cureus
December 1, 2025
Paweł Liszka, Agata Ogórek, Klaudia M Olejnik-Chlewicka et al.
Classic psychedelics and related substances, such as 3,4-methylenedioxymethamphetamine (MDMA), have again become a focus of interest in psychiatry as potential therapeutic tools. The aim of this paper is to review current data on their mechanisms of action, clinical applications in the treatment of mood and anxiety disorders, addictions and post-traumatic stress disorder (PTSD), as well as to...
Dialogues in Clinical Neuroscience
December 1, 2025
Ivona-Maria Tudorancea, Gabriela-Dumitrita Stanciu, Carla Torrent et al.
4 citations
The global population is ageing rapidly, with the number of individuals aged 60 and older reaching 1 billion in 2019 and expected to double by 2050. As people age, neuropsychological health often deteriorates, leading to a higher prevalence of age-related depression. Symptoms may include anxiety, apathy, mood instability, sadness, and, in severe cases, suicidal thoughts. Depression in the...
European Journal of Psychotraumatology
December 1, 2025
Gabrielle Agin-Liebes, Richard J. Zeifman, Jennifer Mitchell
11 citations
Background: Posttraumatic stress disorder (PTSD) is a severe condition often complicated by co-occurring disorders, such as major depression, alcohol use disorder, and substance use disorders. A well-powered phase 3 randomized, placebo-controlled trial has shown that MDMA-assisted therapy (MDMA-AT) may be an effective treatment for severe PTSD. However, the psychological mechanisms driving the...
Journal of Neuroscience
November 24, 2025
Mona Irrmischer, Marco Aqil, Lisa Luan et al.
Psychedelics profoundly alter subjective experience and brain dynamics. Brain oscillations express signatures of near-critical dynamics, relevant for healthy function. Alterations in the proximity to criticality have been suggested to underlie the experiential and neurological effects of psychedelics. Here, we investigate the effects of a psychedelic substance (DMT) on the criticality of brain...
European Journal of Psychotraumatology
November 12, 2025
Guy Simon, Maya Gal-Birman, Nir Tadmor et al.
5 citations
Objective: On 7 October 2023, a mass-casualty attack at the Nova festival in Israel created an unprecedented convergence of collective trauma and altered states of consciousness. Many survivors were under the influence of psychedelics or other psychoactive substances at the time of the attack. This study explored how survivors made sense of and navigated recovery, with a focus on relational,...